Lung Cancer

The drug combined with chemotherapy demonstrated a 60% increase in progression-free survival, suggesting signs of an FDA approval.

Two radiation therapy techniques, SBRT and hypofractionated CRT, may not have many differences for patients with stage 1 NSCLC, but limitations matter.

When I was diagnosed with lung cancer, I didn’t want to receive chemotherapy, especially when I was a good candidate for immunotherapy.

Lazcluze demonstrated significant CNS activity, regardless of T790M status, in treating intracranial and leptomeningeal metastases in patients with EGFR-variant NSCLC.

First-line Keytruda plus chemotherapy is the new standard of care for patients with advanced pleural mesothelioma after the previous treatment strategy of chemotherapy alone.

Research has shown that among patients with advanced non-small cell lung cancer, early palliative care delivered by video is as effective as in-person care.

The Food and Drug Administration has approved Opdivo before and after surgery for some with non-small cell lung cancer.

Receiving perioperative Opdivo for non-small cell lung cancer showed event-free survival benefits compared with placebo.

Throughout September, the FDA approved drugs for the treatment of diseases including lung cancer, multiple myeloma, thyroid cancer and breast cancer.

Patients with stage 4 non-small cell lung cancer may derive an equal benefit with a lower dose of Keytruda versus the standard dose.

Two colleagues of Amy Wallace, an oncology nurse, nominated her for the Extraordinary Healer Award based on her care of patients with lung cancer.

As a cancer survivor, I’ve found three impactful ways to get involved in Mesothelioma Awareness Day to help make a difference.

Tagrisso has been approved for some adults with locally advanced, unresectable stage 3 non-small cell lung cancer.

Following a CURE® Educated Patient® Lung Cancer Summit, the City of Hope expert answered 10 commonly asked questions from patients with lung cancer.

Krazati’s benefits were seen regardless of baseline brain metastases, researchers have reported in findings from the KRYSTAL-12 trial.

Two vastly different approaches to navigating the cancer journey may or may not be mutually exclusive.

Among patients with limited-stage small cell lung cancer, the benefits of consolidation Imfinzi were seen across a number of subgroups.

A recent study compared two dosages of ifinatamab deruxtecan among patients with extensive-stage small cell lung cancer.

The FDA has approved Rybrevant plus chemotherapy in certain patients with locally advanced or metastatic non-small cell lung cancer.

Keytruda plus chemo has been approved for unresectable advanced or metastatic malignant pleural mesothelioma based on findings from the KEYNOTE-483 trial.

Imfinzi with monalizumab and ceralasertib showed promising long-term benefits in advanced NSCLC, but no other combinations significantly improved results.

An artificial intelligence model was shown to predict tumor mutation burden in lung cancer and other diseases.

Patients with limited-stage small cell lung cancer saw improvements in progression-free survival and overall survival with Imfinzi versus placebo.

Treatment with the antibody-drug conjugate TORL-1-23 was safe and tolerable in heavily pretreated, CLDN6-positive advanced solid tumors, including platinum-resistant ovarian cancer.

Rybrevant plus chemotherapy improved overall survival versus chemo alone in EGFR-mutant advanced non-small cell lung cancer after disease progression.

Patients with NSCLC did not see a disease-free survival benefit with Imfinzi after surgery compared with taking a placebo.

Tecentriq Hybreza, a subcutaneous delivery of the drug, was approved for certain types of sarcoma, in addition to lung, skin and liver cancers.

Some patients with non-small cell lung cancer saw a 49% reduction in the risk of disease progression or death with ivonescimab versus Keytruda.

Patients with non-small cell lung cancer saw a reduction in their risk of recurrence or death after surgery when treated with pre- and postsurgical Opdivo.

Dr. Debu Tripathy, editor-in-chief of CURE magazine, discusses the advancements made in small cell lung cancer.